Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07333183 · ClinicalTrials.gov registry record · Phase 2
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
A Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, sponsored by Pulmovant.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07333183 is a Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension that is actively recruiting participants, run by Pulmovant. The registered enrollment target is 20 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07333183, a Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, is actively recruiting participants, sponsored by Pulmovant.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Conditions Studied
Interventions
- DRUG inhaled mosliciguat
- DEVICE Dry Powder Inhaler
Study Locations (1)
Florida
- Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC - Kissimmee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-23 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07333183
The ClinicalTrials.gov registry entry for NCT07333183 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Pulmovant, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which inhaled mosliciguat is the first listed.
NCT07333183 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07333183 about?
NCT07333183 is a clinical study titled "A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD". This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
What is the current status of trial NCT07333183?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-12-23. Estimated completion is 2028-01.
What conditions does trial NCT07333183 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Pulmonary Hypertension, Vascular Diseases, Lung Diseases, Fibrosis.
What interventions are being tested in trial NCT07333183?
The interventions under investigation include: inhaled mosliciguat (DRUG), Dry Powder Inhaler (DEVICE).
Who is sponsoring clinical trial NCT07333183?
This trial is sponsored by Pulmovant, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07333183 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.